Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior Therapy

NCT07185945 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Advanced Urothelial Carcinoma

Interventions

DRUG: Zanzalintinib

Sponsor

Guru Sonpavde

Collaborators

[object Object]
[object Object]